Liza Melchor‐Khan
YOU?
Author Swipe
View article: A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis Open
Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonst…
View article: A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Open
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of CC chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF). A randomized, double‐blind, multinational ph…